Pre-made Acasunlimab benchmark antibody ( Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Acasunlimab benchmark antibody (Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-007-1mg	1mg	Inquiry
GMP-Bios-ab-007-10mg	10mg	Inquiry
GMP-Bios-ab-007-100mg	100mg	Inquiry
GMP-Bios-ab-007-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-CD274/PD-L1;TNFRSF9/CD137 Antibod: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 therapeutic antibody
INN Name	Acasunlimab
Target	PD-L1;CD137
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2020
Year Recommended	na
Companies	Genmab;BioNTech
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na